Lacrat

Ticagrelor, the active ingredient in Lacrat, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It is prescribed to reduce thrombotic cardiovascular events in patients with acute coronary syndrome or myocardial infarction. The medication works by inhibiting platelet aggregation, thereby lowering the risk of clot formation that can lead to heart attacks or strokes.

GNH USA supplies Lacrat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Ticagrelor is used in antiplatelet therapy to manage conditions associated with platelet‑driven thrombosis. - Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. - Myocardial infarction: prevents recurrent ischemic events after an acute heart attack. - Prevention of thrombotic cardiovascular events: lowers the incidence of clot‑related complications in high‑risk patients.

Ticagrelor may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dyspnea: shortness of breath, often occurring early in therapy. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools without severe dehydration.

Serious or Rare Side Effects: - Bleeding: including intracranial hemorrhage or gastrointestinal bleeding. - Bradyarrhythmia: significant slowing of heart rate. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Severe allergic reaction: rash, angioedema, or anaphylaxis.

When prescribing ticagrelor, clinicians should consider several precautionary measures to ensure patient safety. - Assess bleeding risk: evaluate history of hemorrhage, recent surgery, or anticoagulant use. - Monitor renal function: dose adjustment may be needed in severe impairment. - Review concomitant antiplatelet or anticoagulant therapy: avoid excessive anticoagulation. - Caution in patients with a history of asthma or chronic obstructive pulmonary disease: dyspnea may be exacerbated. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at below 25°C: keep in the original container, protect from moisture and light.

Ticagrelor can interact with other medicines, altering its antiplatelet efficacy or increasing adverse event risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma levels and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy, increasing thrombotic risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, direct oral anticoagulants): enhanced anticoagulant effect, monitor coagulation parameters. - NSAIDs or aspirin: additive bleeding risk, assess gastrointestinal protection. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin exposure, monitor for myopathy. - P-glycoprotein inhibitors (e.g., verapamil): may modestly raise ticagrelor concentrations.